LEADER 03350nam 2200625 a 450 001 9910462682303321 005 20170816122333.0 010 $a0-203-07600-1 010 $a1-299-16064-6 010 $a1-135-12324-1 035 $a(CKB)2670000000331434 035 $a(EBL)1128275 035 $a(OCoLC)829461210 035 $a(SSID)ssj0000822659 035 $a(PQKBManifestationID)12348748 035 $a(PQKBTitleCode)TC0000822659 035 $a(PQKBWorkID)10760823 035 $a(PQKB)11584850 035 $a(MiAaPQ)EBC1128275 035 $a(EXLCZ)992670000000331434 100 $a20120619d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aUnderstanding NATO in the 21st century$b[electronic resource] $ealliance strategies, security and global governance /$fedited by Graeme P. Herd and John Kriendler 210 $aNew York $cRoutledge$dc2013 215 $a1 online resource (287 p.) 225 1 $aContemporary Security Studies 225 0$aContemporary security studies 300 $aDescription based upon print version of record. 311 $a1-138-83188-3 311 $a0-415-43633-8 320 $aIncludes bibliographical references and index. 327 $aCover; Understanding NATO in the 21st Century: Alliance strategies, security and global governance; Copyright; Contents; Contributors; Acknowledgments; Abbreviations; 1 NATO in an age of uncertainty:Structural shifts and transatlanticbargains?; 2 NATO's Genesis and adaptation:From Washington to Chicago; 3 U.S. perspectives on NATO; 4 NATO enlargement:Close to the end?; 5 NATO partnerships:For peace, combat, and softbalancing?; 6 NATO-Russia relations:Reset is not a four-letterword; 7 NATO and the ComprehensiveApproach:Weak conceptualization, politicaldivergences, and implementationchallenges 327 $a8 Pulling together?:NATO operations in Afghanistan9 NATO and nuclear weapons; 10 NATO and cyber security; 11 NATO:Towards an adaptive missile defense; 12 NATO and energy security:Defining a role; 13 "Good enough is better thangood":Towards a third "TransatlanticBargain"?; Bibliography; Index 330 $aUnderstanding NATO in the 21st Century enhances existing strategic debates and clarifies thinking as to the direction and scope of NATO's potential evolution in the 21st century.The book seeks to identify the possible contours and trade-offs embedded within a potential third ""Transatlantic Bargain"" in the context of a U.S. strategic pivot in a ""Pacific Century"". To that end, it explores the internal adaptation of the Alliance, evaluates the assimilation of NATO's erstwhile adversaries, and provides a focus on NATO's operational future and insights into the new 410 0$aContemporary Security Studies 606 $aSecurity, International 606 $aWorld politics$y21st century 608 $aElectronic books. 615 0$aSecurity, International. 615 0$aWorld politics 676 $a355.031091821 676 $a355/.031091821 701 $aHerd$b Graeme P$0855387 701 $aKriendler$b John$0855388 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910462682303321 996 $aUnderstanding NATO in the 21st century$91909625 997 $aUNINA LEADER 10930nam 2200505 450 001 9910590074503321 005 20231110233237.0 010 $a9789811929762$b(electronic bk.) 010 $z9789811929755 035 $a(MiAaPQ)EBC7079083 035 $a(Au-PeEL)EBL7079083 035 $a(CKB)24762031500041 035 $a(PPN)264194756 035 $a(EXLCZ)9924762031500041 100 $a20230128d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBlockchain in life sciences /$fWendy Charles 210 1$aSingapore :$cSpringer,$d[2022] 210 4$d©2022 215 $a1 online resource (349 pages) 225 1 $aBlockchain Technologies 311 08$aPrint version: Charles, Wendy Blockchain in Life Sciences Singapore : Springer,c2022 9789811929755 327 $aIntro -- Foreword -- Preface -- Acknowledgments -- Contents -- About the Editor -- Abbreviations -- List of Figures -- List of Tables -- Blockchain Uses and Real World Evidence -- Introduction to Blockchain -- 1 Introduction -- 2 Blockchain Core Characteristics -- 2.1 Ledgers -- 2.2 Cryptography -- 2.3 Immutability (Tamper Evidence and Tamper Resistance) -- 2.4 Distribution -- 3 Blockchain Features -- 3.1 Permissionless Versus Permissioned -- 3.2 Permissionless -- 3.3 Off-Chain Versus On-Chain Storage -- 3.4 Smart Contracts -- 4 Blockchain Benefits for Life Sciences -- 4.1 Trust -- 4.2 Audit Trails-Provenance -- 4.3 Data Transparency Versus Privacy -- 4.4 Security -- 4.5 Performance -- 5 Conclusions -- 6 Key Terminology and Definitions -- References -- Blockchain in Pharmaceutical Research and the Pharmaceutical Value Chain -- 1 Brief Overview of Pharmaceutical Research -- 1.1 Drug Delivery and Discovery -- 1.2 Challenges Associated with Drug Delivery and Discovery -- 1.3 Challenges Associated with Preclinical (i.e., In Vitro, In Vivo) and Phase 0/I-IV Studies -- 2 Introduction of the End-To-End Pharmaceutical Value Chain -- 2.1 Five Main Categories: (1) Research and Discovery, (2) Clinical Development, (3) Manufacturing and Supply Chain, (4) Launch and Commercial Considerations, and (5) Monitoring and Health Records -- 2.2 Differentiating Pharmaceutical Value Chain from Pharmaceutical Supply Chain -- 3 Blockchain Efforts Within Pharmaceutical Industry -- 3.1 Pharmaceutical Users Software Exchange (PhUSE) Blockchain Project -- 3.2 Innovative Medicines Initiative (IMI) Blockchain-Enabled Healthcare -- 3.3 The MELLODDY Project and Millions of Molecules Blockchain + Smart Contracts for Human Participant Regulations and Consent Management -- 3.4 Information Exchange and Data Transformation (INFORMED) Initiative -- 3.5 Moneyball Medicine. 327 $a4 Mapping Blockchain Characteristics to Pain Points in the Pharmaceutical Value Chain -- 4.1 Adapted Fit-For-Purpose Framework and Design Elements -- 4.2 Matching Characteristics (e.g., Decentralized, Distributed, Conditionally Immutable, Scalable, Cryptographically Secured) to Identified Pain Points in Each of the 5 Categories -- 5 Blockchain-But Not in a Vacuum -- 5.1 Blockchain-Complementary Established and Emerging (e.g., Machine Learning, Artificial Intelligence) Technologies for the Pharmaceutical Value Chain -- 6 Debunking Myths Around Challenges with Blockchain -- 6.1 The Myth of the Technical Challenge -- 6.2 The Reality of Challenges Tied to Change Management, Resource Allocation, Paradigm Shift, and Reaching Consensus -- 7 Blockchain and The Idea Pipeline -- 7.1 Pharmacogenomics -- 7.2 Collaborative Pharmaceutical Development -- 7.3 Patient Access, Medication Reclamation, and Prescription Waste Reduction -- 7.4 The Evolution of the Traditional Retail Pharmacy -- 8 Future Directions -- 9 Conclusions -- References -- Blockchain-Based Scalable Network for Bioinformatics and Internet of Medical Things (IoMT) -- 1 Introduction -- 1.1 Data Ownership -- 1.2 Data in Blockchain-Based Network -- 2 Case Implementation of Internet of Medical Things (IoMT) with Real Ownership -- 2.1 The Synsal Network -- 2.2 Sensors, Device Engineering, and Scaling in the Synsal Network -- 3 Tokenization and Value Scaling in the Blockchain-Based Network of Hardware Devices -- 3.1 Tokenization and Value Scaling -- 3.2 Basic Stabilization Tokenomics -- 4 Future Directions -- 5 Conclusions -- References -- Blockchains and Genomics: Promises and Limits of Technology -- 1 Introduction: A Brief History of Capitalization on Genes -- 2 The Scientific and Market Value of Genomic Data -- 2.1 On the Nature of Data, and the Data of Nature -- 2.2 Fair and Sustainable Data Use. 327 $a3 Democratize, Decentralize, and Disintermediate Data (The Three Ds) -- 3.1 Blockchain Genomics: The Current Slate -- 4 Why Genomes Cannot Be Owned -- 5 How Shall We Treat Genes? -- 6 What About Non-Fungible Tokens, NFTs? -- 6.1 The Need for Regulation -- 7 Future Directions -- 8 Conclusions -- References -- Convergence of Blockchain and AI for IoT in Connected Life Sciences -- 1 Introduction -- 1.1 Fueling the Digital Transformation in Health and Life Sciences -- 1.2 Technology Unification -- 2 Harnessing the Power of Data-Driven Technologies in Life Sciences -- 2.1 Data-Driven Technologies in Life Sciences -- 3 Innovating in a Highly Regulated Industry -- 4 Essential Elements for Data Strategy in Life Sciences -- 4.1 Data Building Blocks -- 5 Prioritizing Risk Management in Life Sciences -- 6 Opportunities and Challenges for Emerging Digital Technologies in Life Sciences -- 6.1 Major Milestones in Life Sciences Product Development -- 7 Strategic Planning Frameworks -- 7.1 Blockchain and AI to Mitigate Risks of IoT/BYOD -- 7.2 Blockchain-AI Platforms and Infrastructures -- 8 Future Directions -- 8.1 Human as a Platform -- 8.2 Thinking Beyond the Adoption of Technology -- 9 Conclusions -- References -- A Blockchain-Empowered Federated Learning System and the Promising Use in Drug Discovery -- 1 Introduction -- 2 Overview of Federated Learning and Blockchain -- 2.1 Federated Learning -- 2.2 Barriers and Challenges in Drug Discovery -- 2.3 Challenges in Federated Learning -- 2.4 Blockchain Benefit for Federated Learning -- 2.5 The Benefits of Blockchain-Empowered Federated Learning for Drug Discovery -- 3 The Rahasak-ML Platform -- 3.1 Overview -- 3.2 Key Components -- 4 Rahasak-ML Federated Learning Process -- 4.1 Overview -- 4.2 Incremental Training Flow -- 4.3 Finalizing Model. 327 $a4.4 The Use Case of Blockchain-Empowered Federated Learning in the Medical Field -- 5 Future Directions -- 5.1 Data Heterogeneity -- 5.2 Efficiency and Effectiveness -- 5.3 Model Interpretation -- 6 Conclusions -- References -- Considerations for Ensuring Success of Blockchain in Life Sciences Research -- Valuing Research Data: Blockchain-Based Management Methods -- 1 Introduction -- 1.1 Nature of Health Data -- 1.2 Health Data Management -- 2 Data as an Asset -- 2.1 How to Value Data Assets -- 3 Data Sales Methods -- 3.1 Data Brokers -- 3.2 Centralized Data Marketplaces -- 3.3 Decentralized Data Marketplaces -- 3.4 Non-Fungible Tokens -- 4 Considerations -- 4.1 Ethical Considerations -- 4.2 Ownership -- 4.3 Data Considerations -- 5 Recommendations -- 5.1 Ethical Recommendations -- 5.2 Data Recommendations -- 5.3 Legal Recommendations -- 6 Future Directions -- 6.1 Regulations -- 6.2 Future Research -- 7 Conclusions -- 7.1 Key Terminology and Definitions -- References -- Blockchain Adoption in Life Sciences Organizations: Socio-organizational Barriers and Adoption Strategies -- 1 Introduction -- 2 Background Literature -- 3 Research Methods -- 4 Findings -- 4.1 The State of the Blockchain + Life Sciences Ecosystem -- 4.2 Socio-organizational Barriers for Blockchain Adoption in Life Sciences -- 4.3 Barrier 4: The Lack of an "Ecosystem" Mindset -- 4.4 Adoption Strategies -- 5 Discussion -- 5.1 Limitations and Future Directions -- 6 Conclusion -- References -- Blockchain Governance Strategies -- 1 Introduction -- 2 Defining Governance -- 3 A Deeper Dive: Blockchain Governance -- 3.1 On-Chain Governance -- 3.2 Off-Chain Governance -- 4 Types of Ecosystem Governance Decisions -- 5 Common Blockchain Governance Strategies -- 5.1 Founder Led/Benevolent Dictator -- 5.2 Core Development Team -- 5.3 Federations or Alliances -- 6 Ecosystem Roles. 327 $a7 Typical Ecosystem for Life Sciences Blockchain -- 7.1 Special Considerations for Life Sciences -- 8 Recommendations -- 9 Future Directions -- 10 Conclusions -- References -- Life Sciences Intellectual Property Through the Blockchain Lens -- 1 Introduction -- 2 The Emergence of Blockchain in Life Sciences -- 3 The Intersection of Blockchain and Life Sciences IP Rights in the United States -- 3.1 Patents -- 3.2 Trademarks and Trade Dress -- 3.3 Trade Secrets -- 3.4 Copyrights -- 4 Transferring IP Rights Through Blockchains -- 5 Managing IP Rights Through Blockchain -- 6 Blockchain in Adversarial Proceedings Involving IP Rights -- 6.1 Anticounterfeiting -- 7 Future Directions -- 8 Conclusions -- References -- Regulatory Compliance Considerations for Blockchain in Life Sciences Research -- 1 Introduction -- 1.1 Regulatory Agency Uses of Blockchain -- 1.2 Regulatory Applicability -- 2 Regulatory Review and Documentation -- 2.1 System Design and Documentation -- 2.2 System Protection Features -- 2.3 Record and Signature Integrity -- 2.4 Verification and Validation -- 2.5 Training -- 3 Outsourcing -- 4 Future Directions -- 4.1 Standards -- 4.2 Blockchain Education -- 4.3 Research -- 5 Conclusions -- 5.1 Key Terminology and Definitions -- References -- The Art of Ethics in Blockchain for Life Sciences -- 1 Introduction -- 2 Digital Ethics Programs Design for Blockchain in Life Sciences -- 2.1 General Application of Digital Ethics Across the Life Sciences Continuum -- 2.2 Research -- 2.3 Genomics and Precision Medicine -- 2.4 Digital Identity -- 3 Cultural, Legal, and Socioeconomic Influences -- 4 Blockchain Ethics and Purpose in Life Sciences -- 5 Future Directions: Disruption, Innovation, Evolution -- 6 Conclusions -- References -- Cybersecurity Considerations in Blockchain-Based Solutions -- 1 Introduction -- 2 Blockchain Solution Architecture. 327 $a2.1 Network and Architecture Types. 410 0$aBlockchain Technologies 606 $aBlockchains (Databases) 606 $aLife sciences$xData processing 615 0$aBlockchains (Databases) 615 0$aLife sciences$xData processing. 676 $a005.74 700 $aCharles$b Wendy$01254271 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9910590074503321 996 $aBlockchain in Life Sciences$92908284 997 $aUNINA LEADER 03383oam 2200661I 450 001 9910781577303321 005 20200520144314.0 010 $a0-429-10978-4 010 $a1-4398-6224-9 024 7 $a10.1201/b10814 035 $a(CKB)2550000000065024 035 $a(EBL)800964 035 $a(OCoLC)740901290 035 $a(SSID)ssj0000514886 035 $a(PQKBManifestationID)11358557 035 $a(PQKBTitleCode)TC0000514886 035 $a(PQKBWorkID)10523683 035 $a(PQKB)11553678 035 $a(Au-PeEL)EBL800964 035 $a(CaPaEBR)ebr10511315 035 $a(CaONFJC)MIL692626 035 $a(OCoLC)759865957 035 $a(CaSebORM)9781439862247 035 $a(MiAaPQ)EBC800964 035 $a(PPN)171290550 035 $a(EXLCZ)992550000000065024 100 $a20180331d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aData clustering in C++ $ean object-oriented approach /$fGuojun Gan 205 $a1st edition 210 1$aBoca Raton, Fla. :$cChapman and Hall/CRC,$d2011. 215 $a1 online resource (512 p.) 225 1 $aChapman & Hall/CRC data mining and knowledge discovery series 300 $aA Chapman & Hall book. 311 $a1-322-61344-3 311 $a1-4398-6223-0 320 $aIncludes bibliographical references (p. 469-486) and indexes. 327 $aFront Cover; Dedication; Contents; List of Figures; List of Tables; Preface; I. Data Clustering and C++ Preliminaries; 1. Introduction to Data Clustering; 2. The Unified Modeling Language; 3. Object-Oriented Programming and C++; 4. DesignPatterns; 5. C++ Libraries and Tools; II. A C++ Data Clustering Framework; 6. The Clustering Library; 7. Datasets; 8. Clusters; 9. Dissimilarity Measures; 10. Clustering Algorithms; 11. Utility Classes; III. Data Clustering Algorithms; 12. Agglomerative Hierarchical Algorithms; 13. DIANA; 14. The k-means Algorithm; 15. The c-means Algorithm 327 $a16. The k-prototypes Algorithm17. The Genetic k-modes Algorithm; 18. The FSC Algorithm; 19. The Gaussian Mixture Algorithm; 20. A Parallel k-means Algorithm; A. Exercises and Projects; B. Listings; C. Software; Bibliography 330 $aData clustering is a highly interdisciplinary field, the goal of which is to divide a set of objects into homogeneous groups such that objects in the same group are similar and objects in different groups are quite distinct. Thousands of theoretical papers and a number of books on data clustering have been published over the past 50 years. However, few books exist to teach people how to implement data clustering algorithms. This book was written for anyone who wants to implement or improve their data clustering algorithms. Using object-oriented design and programming techniques, Data Clusterin 410 0$aChapman & Hall/CRC data mining and knowledge discovery series. 606 $aCluster analysis$xData processing 606 $aC++ (Computer program language) 615 0$aCluster analysis$xData processing. 615 0$aC++ (Computer program language) 676 $a519.5/3 700 $aGan$b Guojun$f1979,$01561824 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910781577303321 996 $aData clustering in C++$93828850 997 $aUNINA